![]() Median maximum reversal of dabigatran’s anticoagulant effects within 4 hours of idarucizumab administration was 100% (95% confidence interval 100% to 100%). More than 95% of the patients were receiving dabigatran for stroke prevention in the context of atrial fibrillation. In accordance with idarucizumab’s approved indication, enrolled participants were prescribed dabigatran, then presented with uncontrolled or life-threatening bleeding (group A, n = 301) or the need for urgent surgery or procedure (group B, n = 202). The full cohort analysis of this study was published in August 2017. This medicine has been shown to rapidly and completely reverse the anticoagulant effects of dabigatran in the open-label, phase III RE‑VERSal Effects of idarucizumab on Active Dabigatran (RE‑VERSE AD) study. ![]() ![]() Clinical data to support the use of idarucizumab are still limited.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |